Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Europe | May 31, 2017 | May 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 31, 2017 · Filed May 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,137.1496 |
Last balance in matching sequence
After 2017-05-31 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-05-31 · Exercise / conversion · Acquired 10,000 · Balance 139,137.1496 F1: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Row 2 · 2017-05-31 · Sale · Disposed 10,000 · Balance 129,137.1496 F2: This transaction was executed in multiple trades at prices ranging from $114.7519 to $115.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $44.62 · Expires 2018-05-11 | Direct | 38,800 |
Reported balance
After 2017-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-05-31 · Exercise / conversion · Disposed 10,000 · Balance 38,800 F1: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $114.7519 to $115.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2017 Filed May 31, 2017 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-010625 · doc4.xml · derivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,800 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 31, 2017 Filed May 31, 2017 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,000 | $114.88 | $1,148,760.00 |
DisclosureSEC source: 0001225208-17-010625 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,137.1496 F2 · price: This transaction was executed in multiple trades at prices ranging from $114.7519 to $115.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 31, 2017 Filed May 31, 2017 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-010625 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,137.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 19, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · derivative · entry 7 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock · 10,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 19, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,000 | $113.13 | $1,131,346.00 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · nonDerivative · entry 5 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,137.1496 F4 · price: This transaction was executed in multiple trades at prices ranging from $113.00 to $113.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 19, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $44.62 | $446,150.00 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · nonDerivative · entry 4 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,137.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 8,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · derivative · entry 6 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,800 Underlying: Common Stock · 8,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,000 | $113.15 | $905,220.80 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · nonDerivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,137.1496 F3 · price: This transaction was executed in multiple trades at prices ranging from $113.1340 to $113.1550. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,631 | $113.21 | $524,271.81 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,137.1496 F2 · price: This transaction was executed in multiple trades at prices ranging from $113.2091 to $113.2150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,000 | $44.62 | $356,920.00 |
DisclosureSEC source: 0001225208-17-010120 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,768.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 15, 2017 Filed May 15, 2017 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,600 | $113.13 | $294,148.40 |
DisclosureSEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 4 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,768.1496 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 15, 2017 Filed May 15, 2017 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,900 | $113.13 | $214,947.00 |
DisclosureSEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,368.1496 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 12, 2017 Filed May 15, 2017 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,000 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-009815 · doc4.xml · derivative · entry 5 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,800 Underlying: Common Stock · 7,000 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 12, 2017 Filed May 15, 2017 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,000 | $110.68 | $774,732.00 |
DisclosureSEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,268.1496 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 12, 2017 Filed May 15, 2017 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,000 | $44.62 | $312,305.00 |
DisclosureSEC source: 0001225208-17-009815 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,268.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009628 · doc4.xml · derivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,625 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 494 | $110.58 | $54,626.52 |
DisclosureSEC source: 0001225208-17-009628 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,268.1496 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009628 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,762.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (5,500) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 24,000 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · derivative · entry 5 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F6 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,659 | $109.33 | $1,055,987.56 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 4 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,137.1496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $108.83 to $109.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,636 | $110.08 | $840,580.04 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,796.1496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.89 to $110.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,705 | $108.36 | $726,522.96 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,432.1496 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $107.83 to $108.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 24,000 | $25.48 | $611,520.00 |
DisclosureSEC source: 0001225208-17-008604 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,137.1496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 24,000 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-007147 · doc4.xml · derivative · entry 3 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 24,000 | $93.90 | $2,253,499.20 |
DisclosureSEC source: 0001225208-17-007147 · doc4.xml · nonDerivative · entry 2 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,906.2936 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $93.64 to $94.64. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 30, 2017 Filed Apr 3, 2017 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 24,000 | $25.48 | $611,520.00 |
DisclosureSEC source: 0001225208-17-007147 · doc4.xml · nonDerivative · entry 1 Verguet Patrick B · CIK 0001308771 · CVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,906.2936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.